- Approval Id
- 9bed05229e8e9c9b
- Drug Approval Emc Name
- One-Alpha 2 micrograms/ml oral drops
- Drug Name
- One-Alpha 2 micrograms/ml oral drops
- Company Name
- Neon Healthcare Ltd
- Company Address
- 8 The Chase, John Tate Road, Foxholes Business Park, Hertford, Hertfordshire, SG13 7NN, UK
- Company Website
- http://www.neonhealthcare.com
- Company Telephone
- +44 (0)1992 926 330
- Company Medical Info Direct Line
- +44 (0)1992 926 330
- Company Medical Info Email
- medinfo@neonhealthcare.com
- Company Customer Care Direct Line
- +44 (0)1992 926 330
- Company Stock Availability
- +44 (0)1992 926 330
- Atc Code
- A11CC03
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Neon Healthcare Limited
\*\*8\*\* The Chase, John Tate Road,
Hertford, SG13 7NN,
United Kingdom
- Authorisation Number
- PL 45043/0068
- Authorisation Date
- Date of first authorisation: 3 March 2000
Date of latest renewal: 3 March 2005
- Instruction Authorisation Holder
- Neon Healthcare Limited
\*\*8\*\* The Chase, John Tate Road,
Hertford, SG13 7NN,
United Kingdom
- Instruction Authorisation Number
- PL 45043/0068
- Instruction Authorisation Date
- Date of first authorisation: 3 March 2000
Date of latest renewal: 3 March 2005
- Instruction Composition
- Alfacalcidol 2 micrograms/ml
\*\*Excipients with known effect:\*\*
Ethanol, methylparahydroxybenzoate (E218), macrogolglycerol hydroxystearate, sorbitol (E420), sodium citrate (E331).
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Oral drops, solution.
Slightly turbid to clear, colourless solution.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
One-Alpha\\* is indicated in all conditions where there is a disturbance of calcium metabolism due to impaired 1-α hydroxylation such as when there is reduced renal function. The main indications are:
a) Renal osteodystrophy
b) Hyperparathyroidism (with bone disease)
c) Hypoparathyroidism
d) Neonatal hypocalcaemia
e) Nutritional and malabsorptive rickets and osteomalacia
f) Pseudo-deficiency (D-dependent) rickets and osteomalacia
g) Hypophosphataemic vitamin D resistant rickets and osteomalacia4.2 Posology and method of administration
\*\*Posology\*\*
Initial dose for all indications:
| | |
| --- | --- |
| Adults and children over 20 kg bodyweight: | 1 microgram/day |
| Elderly: | 0.5 microgram/day |
| Neonates and premature infants: | 0.05 - 0.1 microgram/kg/day |
| Children under 20 kg bodyweight: | 0.05 microgram/kg/day |
Half-drop doses should be rounded up to the next whole number of drops.
The dose of One-Alpha should be adjusted thereafter to avoid hypercalcaemia according to the biochemical response. Indices of response include plasma levels of calcium (ideally corrected for protein binding), alkaline phosphatase, parathyroid hormone, as well as radiographic and histological investigations.
Plasma levels should initially be measured at weekly intervals. The daily dose of One-Alpha may be increased by increments of 0.25-0.5 microgram. When the dose is stabilised, measurements may be taken every 2-4 weeks.
Most adult patients respond to doses between 1 and 3 micrograms per day. When there is biochemical or radiographic evidence of bone healing (and in hypoparathyroid patients when normal plasma calcium levels have been attained), the dose generally decreases. Maintenance doses are generally in the range of 0.25 to 1 microgram per day. If hypercalcaemia occurs, One-Alpha should be stopped until plasma calcium returns to normal (approximately 1 week) then restarted at half the previous dose.
\*\*(a) Renal bone disease:\*\*
Patients with relatively high initial plasma calcium levels may have autonomous hyperparathyroidism, often unresponsive to One-Alpha. Other therapeutic measures may be indicated.
Before and during treatment with One-Alpha, phosphate binding agents should be considered to prevent hyperphosphataemia. It is particularly important to make frequent plasma calcium measurements in patients with chronic renal failure because prolonged hypercalcaemia may aggravate the decline of renal function.
\*\*(b) Hyperparathyroidism:\*\*
In patients with primary or tertiary hyperparathyroidism about to undergo parathyroidectomy, pre-operative treatment with One-Alpha for 2-3 weeks alleviates bone pain and myopathy without aggravating pre-operative hypercalcaemia. In order to decrease post-operative hypocalcaemia, One-Alpha should be continued until plasma alkaline phosphatase levels fall to normal or hypercalcaemia occurs.
\*\*(c) Hypoparathyroidism:\*\*
In contrast to the response to parent vitamin D, low plasma calcium levels are restored to normal relatively quickly with One-Alpha. Severe hypocalcaemia is corrected more rapidly with higher doses of One-Alpha (e.g. 3-5 micrograms) together with calcium supplements.
\*\*(d) Neonatal hypocalcaemia:\*\*
Although the normal starting dose of One-Alpha is 0.05-0.1 microgram/kg/day (followed by careful titration) in severe cases doses of up to 2 microgram/kg/day may be required. Whilst ionised serum calcium levels may provide a guide to response, measurement of plasma alkaline phosphatase activity may be more useful. Levels of alkaline phosphatase approximately 7.5 times above the adult range indicates active disease.
A dose of 0.1 microgram/kg/day of One-Alpha has proven effective as prophylaxis against early neonatal hypocalcaemia in premature infants.
\*\*(e) Nutritional and malabsorptive rickets and osteomalacia:\*\*
Nutritional rickets and osteomalacia can be cured rapidly with One-Alpha. Malabsorptive osteomalacia (responding to large doses of IM or IV parent vitamin D) will respond to small doses of One-Alpha.
\*\*(f) Pseudo-deficiency (D-dependent) rickets and osteomalacia:\*\*
Although large doses of parent vitamin D would be required, effective doses of One-Alpha are similar to those required to heal nutritional vitamin D deficiency rickets and osteomalacia.
\*\*(g) Hypophosphataemic vitamin D-resistant rickets and osteomalacia:\*\*
Neither large doses of parent vitamin D nor phosphate supplements are entirely satisfactory. Treatment with One-Alpha at normal dosage rapidly relieves myopathy when present and increases calcium and phosphate retention. Phosphate supplements may also be required in some patients.
\*\*Method of administration\*\*
One-Alpha Drops should be administered orally, using the integral dropper. One drop = 0.1 microgram.4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypercalcaemia, metastatic calcification.4.4 Special warnings and precautions for use
During treatment with One-Alpha, serum calcium and serum phosphate levels should be monitored regularly especially in children, patients with renal impairment and patients receiving high doses. PTH, alkaline phosphatase and calcium phosphates should be monitored as clinically indicated.
Hypercalcaemia might appear in patients treated with One-Alpha. For this reason, patients should be informed about the clinical symptoms connected with hypercalcaemia. Signs of hypercalcaemia are muscle and bone pain, muscle weakness, confusion, dehydration, anorexia, fatigue, nausea and vomiting, constipation, polyuria, sweating, headache, polydipsia, hypertension and somnolence.
Hypercalcaemia can be rapidly corrected by stopping treatment until plasma calcium levels return to normal (in about one week). One-Alpha may then be restarted at a reduced dose (half the previous dose) with monitoring of calcium.
Prolonged hypercalcaemia may aggravate arteriosclerosis, cardiac valve sclerosis or nephrolithiasis and therefore prolonged hypercalcaemia should be avoided when One- Alpha is used in these patients. Transient or even long-lasting deterioration of kidney function has been observed. One-Alpha should also be used with caution in patients with calcification of pulmonary tissue as this may result in cardiac disease.
In patients with renal bone disease or severely reduced renal function, a phosphate binding agent could be used simultaneously with alfacalcidol to prevent increased serum phosphate and potential metastatic calcification.
One-Alpha should be used with caution in patients with granulomatous diseases such as sarcoidosis where the sensitivity to vitamin D is increased due to increased hydroxylation activity.
Concurrent use of digitalis glycosides in the presence of hypercalcaemia due to vitamin D administration increases the potential for cardiac arrhythmias.
One-Alpha oral drops contain up to 340 mg ethanol per dose (corresponding to 6 micrograms of alfacalcidol), which is equivalent to 14 vol%. The amount of ethanol in each dose of One-Alpha is equivalent to less than 9 ml beer or 4.5 ml wine. The small amount of ethanol in One-Alpha will not have any noticeable effect.
One-Alpha oral drops contain 452 mg sorbitol as an excipient, which is equivalent to 452 mg per daily maintenance dose (2 micrograms of alfacalcidol), or 6.5 mg sorbitol/kg/day for an adult (70 kg). Patients with rare hereditary problems of fructose intolerance should not take this medicine.
One-Alpha oral drops contain methylparahydroxybenzoate as an excipient. Methylparahydroxybenzoate may cause allergic reactions (possibly delayed).
One-Alpha oral drops contain macrogolglycerol hydroxystearate as an excipient. Macrogolglycerol hydroxystearate may cause stomach upset and diarrhoea.
One-Alpha oral drops contain less than 1 mmol sodium (23 mg) per ml, that is to say essentially 'sodium-free'.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Thiazide diuretics and calcium containing preparations\*\*
Concurrent use of thiazide diuretics or calcium containing preparations may enhance the risk of hypercalcaemia. Calcium levels should be monitored.
\*\*Other vitamin D containing preparations\*\*
Concurrent use of other vitamin D containing preparations may enhance the risk of hypercalcaemia. Use of multiple vitamin D analogues should be avoided.
\*\*Anticonvulsants\*\*
Anticonvulsants (e.g. barbiturates, phenytoin, carbamazepine or primidone) have enzyme-inducing effects resulting in an increased metabolism of alfacalcidol. Patients taking anticonvulsants may require larger doses of One-Alpha.
\*\*Magnesium-containing antacids\*\*
Absorption of magnesium-containing antacids may be enhanced by One-Alpha, increasing the risk of hypermagnesaemia.
\*\*Aluminium-containing preparations\*\*
One-Alpha may increase the serum concentration of aluminium. Patients taking aluminium-containing preparations (e.g. aluminium hydroxide, sucralfate) should be monitored for signs of aluminium related toxicities.
\*\*Bile acid sequestrants\*\*
Concomitant oral administration of bile acid sequestrants such as cholestyramine may impair the intestinal absorption of oral One-Alpha formulations. One-Alpha should be administered at least 1 hour before, or 4 to 6 hours after the intake of the bile acid sequestrant in order to minimise the potential risk of interaction.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There is a limited amount of data from the use of alfacalcidol in pregnant women. Studies in animals have shown reproductive toxicity at high doses.
Therefore, One-Alpha is not recommended during pregnancy and in women of child- bearing potential not using contraception.
\*\*Breast-feeding\*\*
Although it has not been established, it is likely that increased amounts of 1,25- dihydroxyvitamin D will be found in the milk of lactating mothers treated with One-Alpha®\\*. This may influence calcium metabolism in the infant.
Consequently, breast-fed infants of alfacalcidol-using mothers should be monitored closely for hypercalcaemia.
\*\*Fertility\*\*
There are no clinical studies on the effect of One-Alpha on fertility. A pre-clinical study did not show an effect on fertility in rats.4.7 Effects on ability to drive and use machines
Alfacalcidol has no or negligible direct influence on the ability to drive and use machines. However, the patient should be informed that dizziness may occur during treatment and take this into account while driving or using machines.4.8 Undesirable effects
The estimation of the frequency of undesirable effects is based on a pooled analysis of data from clinical studies and spontaneous reporting.
The most frequently reported undesirable effects are various skin reactions such as pruritus and rash, hypercalcaemia, gastrointestinal pain/discomfort and hyperphosphataemia.
Renal failure has been reported post-marketing.
Undesirable effects are listed by MedDRA system organ class (SOC) and the individual undesirable effects are listed starting with the most frequently reported one. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Very common ≥1/10
Common ≥1/100 and < 1/10
Uncommon ≥1/1,000 to <1/100
Rare ≥1/10,000 to <1/1,000
Very rare <1/10,000
Not known (cannot be estimated from the available data)
| | |
| --- | --- |
| \*\*Metabolism and nutrition disorders\*\* | |
| Common: | Hypercalcaemia Hyperphosphataemia |
| \*\*Psychiatric disorders\*\* | |
| Not known: | Confusional state |
| \*\*Nervous system disorders\*\* | |
| Uncommon: | Headache |
| Rare: | Dizziness |
| \*\*Gastrointestinal disorders\*\* | |
| Common: | Abdominal pain and discomfort |
| Uncommon: | Diarrhoea Vomiting Constipation Nausea |
| \*\*Skin and subcutaneous tissue disorders\*\* | |
| Common: | Rash\\* Pruritus \\*Various types of rash such as erythematous, maculo-papular and pustular have been reported |
| Not known: | Urticaria |
| \*\*Musculoskeletal and connective tissue disorders\*\* | |
| Uncommon: | Myalgia |
| \*\*Renal and urinary disorders\*\* | |
| Common: | Hypercalciuria |
| Uncommon: | Nephrolithiasis/Nephrocalcinosis |
| Not known: | Renal impairment (including acute renal failure) |
| \*\*General disorders and administration site conditions\*\* | |
| Uncommon: | Fatigue/asthenia/malaise Calcinosis |
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Excessive intake of One-Alpha may lead to the development of hypercalcaemia, however, the effect is reversed rapidly on withdrawal.
In severe cases of hypercalcaemia general supportive measures should be undertaken: Keep the patient well hydrated by i.v. infusion of saline (force diuresis), measure electrolytes, calcium and renal function indices, assess electrocardiographic abnormalities, especially in patients using digitalis. More specifically, treatment with glucocorticosteroids, loop diuretics, bisphosphonates, calcitonin and eventually haemodialysis with low calcium content should be considered.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Vitamin D and analogues, ATC code A11CC03.
Alfacalcidol is converted rapidly in the liver to 1,25-dihydroxyvitamin D. This is the metabolite of vitamin D which acts as a regulator of calcium and phosphate metabolism. Since this conversion is rapid, the clinical effects of One-Alpha\\* and 1,25-dihydroxyvitamin D are very similar.
Impaired 1α hydroxylation by the kidneys reduces endogenous 1,25- dihydroxyvitamin D production. This contributes to the disturbances in mineral metabolism found in several disorders, including renal bone disease, hypoparathyroidism, neonatal hypocalcaemia and vitamin D dependent rickets. These disorders, which require high doses of parent vitamin D for their correction, will respond to small doses of One-Alpha\\*.
The delay in response and high dosage required in treating these disorders with parent vitamin D makes dosage adjustment difficult. This can result in unpredictable hypercalcaemia which may take weeks or months to reverse. The major advantage of One-Alpha\\* is the more rapid onset of response, which allows a more accurate titration of dosage. Should inadvertent hypercalcaemia occur it can be reversed within days of stopping treatment.5.2 Pharmacokinetic properties
In patients with renal failure, 1-5µg/day of 1α-hydroxyvitamin D (1α-OHD3) increased intestinal calcium and phosphorus absorption in a dose-related manner. This effect was observed within 3 days of starting the drug and, conversely, it was reversed within 3 days of its discontinuation.
In patients with nutritional osteomalacia, increases in calcium absorption were noted within 6 hours of giving 1 µg 1α-OHD3 orally and usually peaked at 24 hours. 1α- OHD3 also produced increases in plasma inorganic phosphorus due to increased intestinal absorption and renal tubular re-absorption. This latter effect is a result of PTH suppression by 1α-OHD3. The effect of the drug on calcium was about double its effect on phosphorus absorption.
Patients with chronic renal failure have shown increased serum calcium levels within 5 days of receiving 1α-OHD3 in a dose of 0.5-1.0 µg/day. As serum calcium rose, PTH levels and alkaline phosphatase decreased toward normal.5.3 Preclinical safety data
The non-clinical toxicity of alfacalcidol is attributed to the known vitamin D-effect of calcitriol on calcium homeostasis, which is characterised by hypercalcaemia, hypercalciuria and eventually soft tissue calcification.
Alfacalcidol is not genotoxic.
No specific effects of alfacalcidol on fertility or behaviour of the offspring were noted in rats and rabbits. In terms of embryo-fetal development, fetal toxicity (post- implantation loss, lower litter size and lower pup weight) was observed at doses high enough to cause toxicity in the dams. High doses of vitamin D are known to be teratogenic in experimental animals.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Ethanol
Macrogolglycerol hydroxystearate
Methylparahydroxybenzoate (E218)
Citric acid monohydrate (E330)
Sodium citrate (E331)
Sorbitol (E420)
All-rac-α-tocopherol
Purified water.6.2 Incompatibilities
None known.6.3 Shelf life
3 years.
After opening, the shelf-life is 4 months when stored at 2-8°C (in a refrigerator).6.4 Special precautions for storage
Store at 2 to 8°C (in a refrigerator). Keep the container in the outer carton.
For storage conditions after first opening of the medicinal product, see section 6.3.6.5 Nature and contents of container
Amber glass bottles of 10 ml and 20 ml, with a polyethylene dropping device and a polypropylene screw cap.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
None.
- Instruction Content
- ## Composition
Alfacalcidol 2 micrograms/ml
\*\*Excipients with known effect:\*\*
Ethanol, methylparahydroxybenzoate (E218), macrogolglycerol hydroxystearate, sorbitol (E420), sodium citrate (E331).
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Oral drops, solution.
Slightly turbid to clear, colourless solution.
## Clinical Particulars
4.1 Therapeutic indications
One-Alpha\\* is indicated in all conditions where there is a disturbance of calcium metabolism due to impaired 1-α hydroxylation such as when there is reduced renal function. The main indications are:
a) Renal osteodystrophy
b) Hyperparathyroidism (with bone disease)
c) Hypoparathyroidism
d) Neonatal hypocalcaemia
e) Nutritional and malabsorptive rickets and osteomalacia
f) Pseudo-deficiency (D-dependent) rickets and osteomalacia
g) Hypophosphataemic vitamin D resistant rickets and osteomalacia4.2 Posology and method of administration
\*\*Posology\*\*
Initial dose for all indications:
| | |
| --- | --- |
| Adults and children over 20 kg bodyweight: | 1 microgram/day |
| Elderly: | 0.5 microgram/day |
| Neonates and premature infants: | 0.05 - 0.1 microgram/kg/day |
| Children under 20 kg bodyweight: | 0.05 microgram/kg/day |
Half-drop doses should be rounded up to the next whole number of drops.
The dose of One-Alpha should be adjusted thereafter to avoid hypercalcaemia according to the biochemical response. Indices of response include plasma levels of calcium (ideally corrected for protein binding), alkaline phosphatase, parathyroid hormone, as well as radiographic and histological investigations.
Plasma levels should initially be measured at weekly intervals. The daily dose of One-Alpha may be increased by increments of 0.25-0.5 microgram. When the dose is stabilised, measurements may be taken every 2-4 weeks.
Most adult patients respond to doses between 1 and 3 micrograms per day. When there is biochemical or radiographic evidence of bone healing (and in hypoparathyroid patients when normal plasma calcium levels have been attained), the dose generally decreases. Maintenance doses are generally in the range of 0.25 to 1 microgram per day. If hypercalcaemia occurs, One-Alpha should be stopped until plasma calcium returns to normal (approximately 1 week) then restarted at half the previous dose.
\*\*(a) Renal bone disease:\*\*
Patients with relatively high initial plasma calcium levels may have autonomous hyperparathyroidism, often unresponsive to One-Alpha. Other therapeutic measures may be indicated.
Before and during treatment with One-Alpha, phosphate binding agents should be considered to prevent hyperphosphataemia. It is particularly important to make frequent plasma calcium measurements in patients with chronic renal failure because prolonged hypercalcaemia may aggravate the decline of renal function.
\*\*(b) Hyperparathyroidism:\*\*
In patients with primary or tertiary hyperparathyroidism about to undergo parathyroidectomy, pre-operative treatment with One-Alpha for 2-3 weeks alleviates bone pain and myopathy without aggravating pre-operative hypercalcaemia. In order to decrease post-operative hypocalcaemia, One-Alpha should be continued until plasma alkaline phosphatase levels fall to normal or hypercalcaemia occurs.
\*\*(c) Hypoparathyroidism:\*\*
In contrast to the response to parent vitamin D, low plasma calcium levels are restored to normal relatively quickly with One-Alpha. Severe hypocalcaemia is corrected more rapidly with higher doses of One-Alpha (e.g. 3-5 micrograms) together with calcium supplements.
\*\*(d) Neonatal hypocalcaemia:\*\*
Although the normal starting dose of One-Alpha is 0.05-0.1 microgram/kg/day (followed by careful titration) in severe cases doses of up to 2 microgram/kg/day may be required. Whilst ionised serum calcium levels may provide a guide to response, measurement of plasma alkaline phosphatase activity may be more useful. Levels of alkaline phosphatase approximately 7.5 times above the adult range indicates active disease.
A dose of 0.1 microgram/kg/day of One-Alpha has proven effective as prophylaxis against early neonatal hypocalcaemia in premature infants.
\*\*(e) Nutritional and malabsorptive rickets and osteomalacia:\*\*
Nutritional rickets and osteomalacia can be cured rapidly with One-Alpha. Malabsorptive osteomalacia (responding to large doses of IM or IV parent vitamin D) will respond to small doses of One-Alpha.
\*\*(f) Pseudo-deficiency (D-dependent) rickets and osteomalacia:\*\*
Although large doses of parent vitamin D would be required, effective doses of One-Alpha are similar to those required to heal nutritional vitamin D deficiency rickets and osteomalacia.
\*\*(g) Hypophosphataemic vitamin D-resistant rickets and osteomalacia:\*\*
Neither large doses of parent vitamin D nor phosphate supplements are entirely satisfactory. Treatment with One-Alpha at normal dosage rapidly relieves myopathy when present and increases calcium and phosphate retention. Phosphate supplements may also be required in some patients.
\*\*Method of administration\*\*
One-Alpha Drops should be administered orally, using the integral dropper. One drop = 0.1 microgram.4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypercalcaemia, metastatic calcification.4.4 Special warnings and precautions for use
During treatment with One-Alpha, serum calcium and serum phosphate levels should be monitored regularly especially in children, patients with renal impairment and patients receiving high doses. PTH, alkaline phosphatase and calcium phosphates should be monitored as clinically indicated.
Hypercalcaemia might appear in patients treated with One-Alpha. For this reason, patients should be informed about the clinical symptoms connected with hypercalcaemia. Signs of hypercalcaemia are muscle and bone pain, muscle weakness, confusion, dehydration, anorexia, fatigue, nausea and vomiting, constipation, polyuria, sweating, headache, polydipsia, hypertension and somnolence.
Hypercalcaemia can be rapidly corrected by stopping treatment until plasma calcium levels return to normal (in about one week). One-Alpha may then be restarted at a reduced dose (half the previous dose) with monitoring of calcium.
Prolonged hypercalcaemia may aggravate arteriosclerosis, cardiac valve sclerosis or nephrolithiasis and therefore prolonged hypercalcaemia should be avoided when One- Alpha is used in these patients. Transient or even long-lasting deterioration of kidney function has been observed. One-Alpha should also be used with caution in patients with calcification of pulmonary tissue as this may result in cardiac disease.
In patients with renal bone disease or severely reduced renal function, a phosphate binding agent could be used simultaneously with alfacalcidol to prevent increased serum phosphate and potential metastatic calcification.
One-Alpha should be used with caution in patients with granulomatous diseases such as sarcoidosis where the sensitivity to vitamin D is increased due to increased hydroxylation activity.
Concurrent use of digitalis glycosides in the presence of hypercalcaemia due to vitamin D administration increases the potential for cardiac arrhythmias.
One-Alpha oral drops contain up to 340 mg ethanol per dose (corresponding to 6 micrograms of alfacalcidol), which is equivalent to 14 vol%. The amount of ethanol in each dose of One-Alpha is equivalent to less than 9 ml beer or 4.5 ml wine. The small amount of ethanol in One-Alpha will not have any noticeable effect.
One-Alpha oral drops contain 452 mg sorbitol as an excipient, which is equivalent to 452 mg per daily maintenance dose (2 micrograms of alfacalcidol), or 6.5 mg sorbitol/kg/day for an adult (70 kg). Patients with rare hereditary problems of fructose intolerance should not take this medicine.
One-Alpha oral drops contain methylparahydroxybenzoate as an excipient. Methylparahydroxybenzoate may cause allergic reactions (possibly delayed).
One-Alpha oral drops contain macrogolglycerol hydroxystearate as an excipient. Macrogolglycerol hydroxystearate may cause stomach upset and diarrhoea.
One-Alpha oral drops contain less than 1 mmol sodium (23 mg) per ml, that is to say essentially 'sodium-free'.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Thiazide diuretics and calcium containing preparations\*\*
Concurrent use of thiazide diuretics or calcium containing preparations may enhance the risk of hypercalcaemia. Calcium levels should be monitored.
\*\*Other vitamin D containing preparations\*\*
Concurrent use of other vitamin D containing preparations may enhance the risk of hypercalcaemia. Use of multiple vitamin D analogues should be avoided.
\*\*Anticonvulsants\*\*
Anticonvulsants (e.g. barbiturates, phenytoin, carbamazepine or primidone) have enzyme-inducing effects resulting in an increased metabolism of alfacalcidol. Patients taking anticonvulsants may require larger doses of One-Alpha.
\*\*Magnesium-containing antacids\*\*
Absorption of magnesium-containing antacids may be enhanced by One-Alpha, increasing the risk of hypermagnesaemia.
\*\*Aluminium-containing preparations\*\*
One-Alpha may increase the serum concentration of aluminium. Patients taking aluminium-containing preparations (e.g. aluminium hydroxide, sucralfate) should be monitored for signs of aluminium related toxicities.
\*\*Bile acid sequestrants\*\*
Concomitant oral administration of bile acid sequestrants such as cholestyramine may impair the intestinal absorption of oral One-Alpha formulations. One-Alpha should be administered at least 1 hour before, or 4 to 6 hours after the intake of the bile acid sequestrant in order to minimise the potential risk of interaction.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There is a limited amount of data from the use of alfacalcidol in pregnant women. Studies in animals have shown reproductive toxicity at high doses.
Therefore, One-Alpha is not recommended during pregnancy and in women of child- bearing potential not using contraception.
\*\*Breast-feeding\*\*
Although it has not been established, it is likely that increased amounts of 1,25- dihydroxyvitamin D will be found in the milk of lactating mothers treated with One-Alpha®\\*. This may influence calcium metabolism in the infant.
Consequently, breast-fed infants of alfacalcidol-using mothers should be monitored closely for hypercalcaemia.
\*\*Fertility\*\*
There are no clinical studies on the effect of One-Alpha on fertility. A pre-clinical study did not show an effect on fertility in rats.4.7 Effects on ability to drive and use machines
Alfacalcidol has no or negligible direct influence on the ability to drive and use machines. However, the patient should be informed that dizziness may occur during treatment and take this into account while driving or using machines.4.8 Undesirable effects
The estimation of the frequency of undesirable effects is based on a pooled analysis of data from clinical studies and spontaneous reporting.
The most frequently reported undesirable effects are various skin reactions such as pruritus and rash, hypercalcaemia, gastrointestinal pain/discomfort and hyperphosphataemia.
Renal failure has been reported post-marketing.
Undesirable effects are listed by MedDRA system organ class (SOC) and the individual undesirable effects are listed starting with the most frequently reported one. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Very common ≥1/10
Common ≥1/100 and < 1/10
Uncommon ≥1/1,000 to <1/100
Rare ≥1/10,000 to <1/1,000
Very rare <1/10,000
Not known (cannot be estimated from the available data)
| | |
| --- | --- |
| \*\*Metabolism and nutrition disorders\*\* | |
| Common: | Hypercalcaemia Hyperphosphataemia |
| \*\*Psychiatric disorders\*\* | |
| Not known: | Confusional state |
| \*\*Nervous system disorders\*\* | |
| Uncommon: | Headache |
| Rare: | Dizziness |
| \*\*Gastrointestinal disorders\*\* | |
| Common: | Abdominal pain and discomfort |
| Uncommon: | Diarrhoea Vomiting Constipation Nausea |
| \*\*Skin and subcutaneous tissue disorders\*\* | |
| Common: | Rash\\* Pruritus \\*Various types of rash such as erythematous, maculo-papular and pustular have been reported |
| Not known: | Urticaria |
| \*\*Musculoskeletal and connective tissue disorders\*\* | |
| Uncommon: | Myalgia |
| \*\*Renal and urinary disorders\*\* | |
| Common: | Hypercalciuria |
| Uncommon: | Nephrolithiasis/Nephrocalcinosis |
| Not known: | Renal impairment (including acute renal failure) |
| \*\*General disorders and administration site conditions\*\* | |
| Uncommon: | Fatigue/asthenia/malaise Calcinosis |
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Excessive intake of One-Alpha may lead to the development of hypercalcaemia, however, the effect is reversed rapidly on withdrawal.
In severe cases of hypercalcaemia general supportive measures should be undertaken: Keep the patient well hydrated by i.v. infusion of saline (force diuresis), measure electrolytes, calcium and renal function indices, assess electrocardiographic abnormalities, especially in patients using digitalis. More specifically, treatment with glucocorticosteroids, loop diuretics, bisphosphonates, calcitonin and eventually haemodialysis with low calcium content should be considered.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Vitamin D and analogues, ATC code A11CC03.
Alfacalcidol is converted rapidly in the liver to 1,25-dihydroxyvitamin D. This is the metabolite of vitamin D which acts as a regulator of calcium and phosphate metabolism. Since this conversion is rapid, the clinical effects of One-Alpha\\* and 1,25-dihydroxyvitamin D are very similar.
Impaired 1α hydroxylation by the kidneys reduces endogenous 1,25- dihydroxyvitamin D production. This contributes to the disturbances in mineral metabolism found in several disorders, including renal bone disease, hypoparathyroidism, neonatal hypocalcaemia and vitamin D dependent rickets. These disorders, which require high doses of parent vitamin D for their correction, will respond to small doses of One-Alpha\\*.
The delay in response and high dosage required in treating these disorders with parent vitamin D makes dosage adjustment difficult. This can result in unpredictable hypercalcaemia which may take weeks or months to reverse. The major advantage of One-Alpha\\* is the more rapid onset of response, which allows a more accurate titration of dosage. Should inadvertent hypercalcaemia occur it can be reversed within days of stopping treatment.5.2 Pharmacokinetic properties
In patients with renal failure, 1-5µg/day of 1α-hydroxyvitamin D (1α-OHD3) increased intestinal calcium and phosphorus absorption in a dose-related manner. This effect was observed within 3 days of starting the drug and, conversely, it was reversed within 3 days of its discontinuation.
In patients with nutritional osteomalacia, increases in calcium absorption were noted within 6 hours of giving 1 µg 1α-OHD3 orally and usually peaked at 24 hours. 1α- OHD3 also produced increases in plasma inorganic phosphorus due to increased intestinal absorption and renal tubular re-absorption. This latter effect is a result of PTH suppression by 1α-OHD3. The effect of the drug on calcium was about double its effect on phosphorus absorption.
Patients with chronic renal failure have shown increased serum calcium levels within 5 days of receiving 1α-OHD3 in a dose of 0.5-1.0 µg/day. As serum calcium rose, PTH levels and alkaline phosphatase decreased toward normal.5.3 Preclinical safety data
The non-clinical toxicity of alfacalcidol is attributed to the known vitamin D-effect of calcitriol on calcium homeostasis, which is characterised by hypercalcaemia, hypercalciuria and eventually soft tissue calcification.
Alfacalcidol is not genotoxic.
No specific effects of alfacalcidol on fertility or behaviour of the offspring were noted in rats and rabbits. In terms of embryo-fetal development, fetal toxicity (post- implantation loss, lower litter size and lower pup weight) was observed at doses high enough to cause toxicity in the dams. High doses of vitamin D are known to be teratogenic in experimental animals.
## Pharmaceutical Particulars
6.1 List of excipients
Ethanol
Macrogolglycerol hydroxystearate
Methylparahydroxybenzoate (E218)
Citric acid monohydrate (E330)
Sodium citrate (E331)
Sorbitol (E420)
All-rac-α-tocopherol
Purified water.6.2 Incompatibilities
None known.6.3 Shelf life
3 years.
After opening, the shelf-life is 4 months when stored at 2-8°C (in a refrigerator).6.4 Special precautions for storage
Store at 2 to 8°C (in a refrigerator). Keep the container in the outer carton.
For storage conditions after first opening of the medicinal product, see section 6.3.6.5 Nature and contents of container
Amber glass bottles of 10 ml and 20 ml, with a polyethylene dropping device and a polypropylene screw cap.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
None.
